Related Experiment Video
Updated: Jul 4, 2026
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
A cellular conformation-based screen for androgen receptor inhibitors
Abstract:
The androgen receptor (AR), a member of the steroid nuclear receptor family of transcription factors, regulates a wide range of physiological processes. Androgen signaling is also associated with numerous human diseases, including prostate cancer. All current antiandrogen therapies reduce ligand access to AR, whether by competitive antagonism or inhibition of androgen production, but are limited by acquired resistance and serious side-effects. Thus, novel antiandrogens that target events subsequent to ligand binding could have important therapeutic value. We developed a high throughput assay that exploits fluorescence resonance energy transfer (FRET) to measure ligand-induced conformation change in AR. We directly compared this assay to a transcription-based assay in a screen of FDA-approved compounds and natural products. The FRET-based screen identified compounds with previously unrecognized antiandrogen activities, with equivalent sensitivity and superior specificity compared to a reporter-based screen. This approach can thus improve the identification of small molecule AR inhibitors.
Insights
A novel FRET-based assay identifies new antiandrogen compounds by measuring androgen receptor (AR) conformation changes. This method offers superior specificity over traditional reporter assays for discovering AR inhibitors.
Area of Science:
- Molecular biology
- Biochemistry
- Pharmacology
Background:
- The androgen receptor (AR) is crucial for physiological processes and implicated in diseases like prostate cancer.
- Current antiandrogen therapies face limitations due to resistance and side effects.
- Novel therapies targeting post-ligand binding events are needed.
Discussion:
- A high-throughput fluorescence resonance energy transfer (FRET) assay was developed to detect ligand-induced AR conformational changes.
- This FRET assay was directly compared against a transcription-based assay using FDA-approved compounds and natural products.
- The FRET assay demonstrated equivalent sensitivity and superior specificity in identifying antiandrogen activities.
Key Insights:
- The FRET assay effectively identifies compounds with previously unrecognized antiandrogen activities.
- This approach enhances the discovery of small molecule AR inhibitors.
- Directly measuring AR conformation change provides a more specific screening method.
Outlook:
- The FRET-based assay can significantly improve the identification of novel antiandrogen drug candidates.
- This technology holds potential for developing more effective treatments for AR-dependent diseases.
- Further application of this assay could accelerate drug discovery for nuclear receptor targets.
